Clinical Trials

114 enrolled

CRC

NCT07381764 2026-02-02

ROMANCE - GOIM

150 enrolled

Phase 1 Not yet recruiting

Colorectal Neoplasms

NCT07363408 2026-01-23

Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer

30 enrolled

Phase 1/2 Not yet recruiting

Colorectal Neoplasms

NCT07346157 2026-01-16

PNOC044

69 enrolled

CNS

Medulloblastoma

NCT07094893 2026-01-14

ARIEL-ENGIC

Phase 4 Not yet recruiting

280 enrolled

Colorectal Neoplasms

NCT07229846 2026-01-08

A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation

30 enrolled

Colorectal Neoplasms

NCT07318831 2026-01-06

Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children

27 enrolled

CNS

Neuroblastoma

NCT07277842 2025-12-11

PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer

382 enrolled

Locally Advanced Low Rectal Adenocarcinoma

NCT07271355 2025-12-09

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial

129 enrolled

Appendiceal Neoplasms, Colorectal Neoplasms

NCT07258147 2025-12-02

Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases

30 enrolled

Thoracic

Lung Neoplasms

NCT07150403 2025-09-08

Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

74 enrolled

Colorectal Neoplasms

NCT07155629 2025-09-04

LEFT-PANC

381 enrolled

Pancreatic Cancer Resectable

NCT07062536 2025-07-14

mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line

130 enrolled

Biliary Cancer Metastatic

NCT07059338 2025-07-10

HERBIC

34 enrolled

Colorectal Neoplasms

NCT07004413 2025-06-04

FIRE-11

267 enrolled

Colorectal Neoplasms

NCT06899477 2025-03-28

Pre-Operative Treatment in REseCTable COlon CanceR

714 enrolled

Colonic Neoplasms

NCT06751394 2024-12-27

TRACER

44 enrolled

Rectal Neoplasms

NCT06745193 2024-12-20

A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer

63 enrolled

Advanced Esophageal Carcinoma

NCT06692491 2024-11-18

SPRING

200 enrolled

Rare Tumour

NCT06665087 2024-10-30

CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC

110 enrolled

Colonic Neoplasms, Rectal Neoplasms

NCT06652412 2024-10-28

CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC

124 enrolled

Colonic Neoplasms, Rectal Neoplasms

NCT06501664 2024-07-15

Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC

360 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06166589 2023-12-12

Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer

19 enrolled

Pancreatic Neoplasms

NCT05427669 2022-10-07

AFFORD

340 enrolled

Colorectal Neoplasms, Neoplasm, Residual

NCT04443543 2020-06-30

An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer

222 enrolled

Rectal Neoplasms

NCT04034173 2019-07-26

Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation

120 enrolled